Role of microRNAs in regulation of the TNF/TNFR gene superfamily in chronic lymphocytic leukemia

Clinical Biochemistry

Volumn 49, Issue 16-17, 2016, Pages 1307-1310

  Srivastava, Swati ^a,b   Tsongalis, Gregory J ^a,b   Kaur, Prabhjot ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NORRIS COTTON CANCER CENTER   (United States)

Author keywords

CLL; MiRNA; TNF

Indexed keywords

DEAD BOX HELICASE 3; DEAD BOX PROTEIN; F BOX AND WD REPEAT DOMAIN CONTAINING 7; F BOX PROTEIN; INTERLEUKIN 10 RECEPTOR ALPHA; LIPOPOLYSACCHARIDE INDUCED TUMOR NECROSIS FACTOR ALPHA FACTOR; LYMPHOTOXIN BETA RECEPTOR; MICRORNA; MICRORNA 15A; MICRORNA 181A; MICRORNA 223; MICRORNA 29A; OSTEOPROTEGERIN; PROTEIN BCL 2; PROTEIN BCL 6; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 4; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 1A; UNCLASSIFIED DRUG;

ARTICLE; CANCER GENETICS; CHRONIC LYMPHATIC LEUKEMIA; GENE FUNCTION; GENE IDENTIFICATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC REGULATION; HUMAN; LEUKEMOGENESIS; PRIORITY JOURNAL; GENE EXPRESSION REGULATION; GENETICS; MULTIGENE FAMILY; PHYSIOLOGY;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICRORNAS; MULTIGENE FAMILY; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84992170201     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2016.08.010     Document Type: Article

References (54)

1. [1] Hallek, M., Cheson, B.D., Catovsky, D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111 (2008), 5446–5456.
2. [2] WHO classification of tumors of hematopoietic and lymphoid tissues. Mature B-cell Neoplasm, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, 4th ed., 2008, 180–182 (Chapter 10).
3. [3] Linet, M.S., Devesa, S.S., Morgan, G.J., Schottenfeld, D., Fraumeni, J.F. Jr., (eds.) The Leukemias Cancer Epidemiology and Prevention, 3, 2006, Oxford University Press, New York, 841–871.
4. [4] Cancer Statistics Factsheets, S.E.E.R., Chronic Lymphocytic Leukemia. 2015, National Cancer Institute, Bethesda, MD http://seer.cancer.gov/statfacts/html/clyl.htm.
5. [5] Goldin, L.R., Slager, S.L., Familial CLL: genes and environment, Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2007, 339–345.
6. [6] Slager, S.L., Rabe, K.G., Achenbach, S.J., et al. Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood 117 (2011), 1911–1916.
7. [7] Goldin, L.R., Slager, S.L., Caporaso, N.E., Familial chronic lymphocytic leukemia. Curr. Opin. Hematol. 17 (2010), 350–355.
8. [8] Ojha, J., Ayres, J., Secreto, C., et al. Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. Blood, 2014.
9. [9] Lima, R.T., Busacca, S., Almeida, G.M., et al. MicroRNA regulation of core apoptosis pathways in cancer. Eur. J. Cancer 47 (2011), 163–174.
10. [10] Calin, G.A., Dumitru, C.D., Shimizu, M., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 15524–15529.
11. [11] Calin, G.A., Liu, C.G., Sevignani, C., et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 11755–11760.
12. [12] Fulci, V., Chiaretti, S., Goldoni, M., et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 109 (2007), 4944–4951.
13. [13] Marton, S., Garcia, M.R., Robello, C., et al. Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 22:2 (2008), 330–338.
14. [14] Klein, U., Lia, M., Crespo, M., et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17:1 (Jan 19, 2010), 28–40.
15. [15] Cimmino, A., Calin, G.A., Fabbri, M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U. S. A. 102:39 (Sep 27, 2005), 13944–13949.
16. [16] Nicoloso, M.S., Kipps, T.J., Croce, C.M., Calin, G.A., MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Br. J. Haematol. 139:5 (Dec 1, 2007), 709–716.
17. [17] Ch, Foucar K., Mature B- and T-cell lymphoproliferative disorder. Bone Marrow Pathology, 3rd edition volume 2 (2010), 476–488.
18. [18] Calin, G.A., Ferracin, M., Cimmino, A., et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353 (2005), 1793–1801.
19. [19] Rossi, S., Shimizu, M., Barbarotto, E., et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 116 (2010), 945–952.
20. [20] Wang, L., Lawrence, M.S., Wan, Y., et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365 (2011), 2497–2506.
21. [21] Machulla, H.K.G., Müller, L.P., Schaaf, A., et al. Association of chronic lymphocytic leukemia with specific alleles of the HLA-DR4:DR53:DQ8 haplotype in German patients. Int. J. Cancer 92:2 (2001), 203–207.
22. [22] Sellick, G.S., Rudd, M., Eve, P., et al. The P2X7 receptor gene A1513C polymorphism does not contribute to risk of familial or sporadic chronic lymphocytic leukemia. Cancer Epidemiol. Biomark. Prev. 13 (2004), 1065–1067.
23. [23] Wiley, J.S., Dao-Ung, L.P., Gu, B.J., et al. A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. Lancet 359 (2002), 1114–1119.
24. [24] Bogunia-Kubik, K.G., Mazur, I., Urbanowicz, T., et al. Lack of association between the TNF-α promoter gene polymorphism and susceptibility to B-cell chronic lymphocytic leukaemia. Int. J. Immunogenet. 33:1 (2006), 21–24.
25. [25] Guzowski, D., Chandrasekaran, A., Gawel, C., et al. Analysis of single nucleotide polymorphisms in the promoter region of interleukin-10 by denaturing high-performance liquid chromatography. J. Biomol. Technol. 16 (2005), 154–166.
26. [26] Pérez-Chacón, G., Contreras-Martín, B., Cuní, S., et al. Polymorphism in the CD5 gene promoter in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Am. J. Clin. Pathol., 646-650, 2005.
27. [27] Zhang, Y., Lan, Q., Rothman, N., et al. A putative exonic splicing polymorphism in the BCL6 gene and the risk of non-Hodgkin lymphoma. J. Natl. Cancer Inst. 97 (2005), 1616–1618.
28. [28] Jamroziak, K., Balcerczak, E., Smolewski, P., et al. MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacol. Rep., 58(5), 2006, 720.
29. [29] Morton, L.M., Schenk, M., Hein, D.W., et al. Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. Pharmacogenet. Genomics, 16(8), 2006, 537.
30. [30] Nuckel, H., Frey, U.H., Bau, M., et al. Association of a novel regulatory polymorphism (− 938C > A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 109 (2007), 290–297.
31. [31] Nieters, A., Beckmann, L., Deeg, E., et al. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun., 2006, 615–624.
32. [32] Lan, Q., Zheng, T., Chanock, S., et al. Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma. Carcinogenesis 28:4 (2006), 823–827.
33. [33] Sethupathy, P., Megraw, M., Hatzigeorgiou, A.G., A guide through present computational approaches for the identification of mammalian microRNA targets. Nat. Methods 3 (2006), 881–886.
34. [34] Chen, Y., An integrated cross-database search system for microRNA. Biomed. Eng. Inform. 1-4 (2009), 17–19.
35. [35] Bartel, D.P., MicroRNAs: target recognition and regulatory functions. Cell 136:2 (2009), 215–233.
36. [36] Lewis, B.P., Burge, C.B., Bartel, D.P., Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:1 (2005), 15–20.
37. [37] Grimson, A., Farh, K.K.H., Johnston, W.K., et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 27:1 (2007), 91–105.
38. [38] Friedman, R.C., Farh, K.K.H., Burge, C.B., et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:1 (2009), 92–105.
39. [39] Ojha, J., Ayres, J., Secreto, C., Tschumper, R., et al. Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. Blood 125:3 (Jan 15, 2015), 492–498.
40. [40] Wang, L., Lawrence, M.S., Wan, Y., et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365:26 (2011), 2497–2506.
41. [41] Vollbrecht, C., Mairinger, F.D., Koitzsch, U., et al. Comprehensive analysis of disease-related genes in chronic lymphocytic leukemia by multiplex PCR-based next generation sequencing. PLoS One, 10(6), Jun 8, 2015, e0129544 (doi: 0.1371/journal.pone.0129544. eCollection 2015.PMID:26053404).
42. [42] Pekarsky, Y., Croce, C.M., Role of miR-15/16 in CLL. Cell Death Differ. 22:1 (2015), 6–11.
43. [43] Cordingley, F.T., Bianchi, A., Hoffbrand, A.V., et al. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet 1 (1988), 969–971.
44. [44] Foa, R., Massaia, M., Cardona, S., et al. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood 76 (1990), 393–400.
45. [45] Ferrajoli, A., Keating, M.J., Manshouri, T., et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 100 (2002), 1215–1219.
46. [46] Bojarska-Junak, A., Rolinski, J., Wasik-Szczepaneko, E., et al. Intracellular tumor necrosis factor production by T- and B-cells in B-cell chronic lymphocytic leukemia. Haematologica 87 (2002), 490–499.
47. [47] Dempsey, P.W., Doyle, S.E., He, J.Q., et al. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 14:3–4 (2003), 193–209.
48. [48] Hehlgans, T., Pfeffer, K., The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115 (2005), 1–20.
49. [49] Hauer, J., Puschner, S., Ramakrishnan, P., et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 2874–2879.
50. [50] Wang, S.S., Purdue, M.P., Cerhan, J.R., et al. Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk. PLoS One, 4, 2009, e5360.
51. [51] Yang, X.-D., Sun, S.-C., Targeting signaling factors for degradation, an emerging mechanism for TRAF functions. Immunol. Rev. 266 (2015), 56–71.
52. [52] Locksley, R.M., Killeen, N., Lenardo, M.J., The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104 (2001), 487–501.
53. [53] Srivastava, S., Tsongalis, G., Kaur, P., Recent advances in microRNA-mediated gene regulation in chronic lymphocytic leukemia. Clin. Biochem. 46 (2013), 901–908.
54. [54] Li, Z., Rana, T.M., Therapeutic targeting of microRNAs: current status and future challenges. Nat. Rev. Drug Dis. 13 (2014), 622–638.